Trial Profile
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Laquinimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ALLEGRO
- Sponsors Teva Pharmaceutical Industries
- 21 Apr 2016 Post-hoc analysis results (n=1990) (for this data was pooled from ALLEGRO and BRAVO trials) from this and BRAVO trials presented at the 68th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Results from ALLEGRO and BRAVO trials at 10 years presented at the 68th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Results of a pooled analysis from ALLEGRO and BRAVO trials presented at the 68th Annual Meeting of the American Academy of Neurology